Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Multiple Myeloma

2.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

3.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

4.

Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

5.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot